Alterity Therapeutics (PRNAD) EPS (Basic) (2009 - 2010)

Alterity Therapeutics (PRNAD) has reported EPS (Basic) for 5 consecutive years, with -$2.54 the latest figure, recorded in Q2 2019.

• In Q2 2019, EPS (Basic) rose 5.63% year-over-year to -$2.54; the TTM figure through Jun 2021 stood at $0.0 (up 100.04% YoY), while the FY2025 annual figure was -$0.0, up 100.0% from the prior year.
• EPS (Basic) came in at -$2.54 for Q2 2019 at Alterity Therapeutics, up from -$2.7 in the prior quarter.
• The five-year high for EPS (Basic) was -$2.54 in Q2 2019, with the low at -$2.75 in Q2 2016.
• Average EPS (Basic) over 4 years is -$2.67, with a median of -$2.7 recorded in 2018.
• Across the five-year window, EPS (Basic) rose 0.07% in 2018 and gained 5.63% in 2019, its largest moves.
• Year by year, EPS (Basic) stood at -$2.75 in 2016, then gained by 1.95% to -$2.7 in 2017, then gained by 0.07% to -$2.7 in 2018, then rose by 5.63% to -$2.54 in 2019.
• According to Business Quant data, EPS (Basic) over the past three periods registered -$2.54, -$2.7, and -$2.7 for Q2 2019, Q2 2018, and Q2 2017 respectively.